【摘要】贫血是慢性肾脏病(chronic kidney disease,CKD)的主要并发症，给广大CKD 患者带来巨大的健康、生活及经济负担，同时也给社会带来沉重的经济负担。当前肾性贫血的达标率还不理想。在临床中需要准确评估肾性贫血治疗的靶目标，合理有效地应用纠正贫血药物，开发经济、有效的新型抗贫血药物。肾性贫血的治疗对于减轻CKD 患者及社会的负担，提高患者生活质量，改善临床预后有着重要的意义。
【Abstract】Anemia is a common complication among chronic kidney disease patients, which affects health and quality of life of the patients, and imposes a tremendous economic burden for patients and society. Currently, the compliance rate of renal anemia is unsatisfactory. Accurate evaluation of the target of renal anemia treatment, rational and effective use of anti-anemia drugs, and development of economical and effective new anti-anemia drugs are essential in clinical practice. Treatment of renal anemia can be of great significance to reduce the burden of patients and society, improve the quality of life in CKD patients, delay the disease progression, and improve the clinical prognosis.
[1]Smith RE, Jr.The clinical and economic burden of anemia [J].Am J Manag Care, 2010, 16( Suppl Issues):S59-66
[2]Li Y, Shi H, Wang WM, et al.Prevalence,awareness,and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter,cross-sectional study[J].Medicine (Baltimore), 2016, 95(24):e3872-e3880
[3]张伟明，钱家麒.上海市透析登记及其结果分析[J].中国血液净化, 2012, 5:233-236
[4]White Y, Grenyer BF.The biopsychosocial impact of end-stage renal disease: the experience of dialysis patients and their partners[J].J Adv Nurs, 1999, 30(6):1312-1320
[5]Akizawa T, Pisoni RL, Akiba T, et al.Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS[J].Nephrol Dial Transplant, 2008, 23(11):3643-3653
[6]Hirakata H, Tsubakihara Y, Gejyo F, et al.Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients[J].Clin Exp Nephrol, 2010, 14(1):28-35
[7]Leaf DE, Goldfarb DS.Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia[J].Kidney Int, 2009, 75(1):15-24
[8]Okpechi IG, Nthite T, Swanepoel CR.Health-related quality of life in patients on hemodialysis and peritoneal dialysis[J].Saudi J Kidney Dis Transpl, 2013, 24(3):519-526
[9]Yamamoto T, Miyazaki M, Nakayama M, et al.Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study[J].Clin Exp Nephrol, 2016, 20(4):595-602
[10]Iimori S, Naito S, Noda Y, et al.Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study[J].Nephrology (Carlton), 2015, 20(9):601-608
[11]Inaba M, Hayashino Y, Shoji T, et al.Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study[J].Nephron Clinical practice, 2012, 120(2):c91-c100
[12]Kuragano T, Matsumura O, Matsuda A, et al.Association between hemoglobin variability,serum ferritin levels,and adverse eventsmortality in maintenance hemodialysis patients[J].Kidney Int, 2014, 86(4):845-854
[13]Drueke TB, Locatelli F, Clyne N, et al.Normalization of hemoglobin level in patients with chronic kidney disease and anemia[J].N Engl J Med, 2006, 355(20):2071-2084
[14]Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al.Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review[J].J Med Econ, 2019, 22(6):593-604
[15]左力，刘雪丽，韩晟.肾性贫血加重中国慢性肾脏病患者经济负担的研究[J].中国药物经济学, 2018, 13(9):11-16
[16]茅雯辉，余学清，陈文.腹膜透析患者肾性贫血治疗的经济负担研究[J].中国卫生经济, 2012, 31(11):42-44
[17]Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J.Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review[J].Ther Apher Dial, 2018, 22(5):444-456
[18]Ibrahim HN, Ishani A, Guo H, Gilbertson DT.Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older[J].Nephrol Dial Transplant, 2009, 24(10):3138-3143
[19]Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective[J].Dis Manag, 2008, 11(1):49-58
[20]Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F.Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patientsSpanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology[J].J Am Soc Nephrol, 2000, 11(2):335-342
[21]Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.An economic evaluation of erythropoiesis-stimulating agents in CKD[J].Am J Kidney Dis, 2010, 56(6):1050-1061
[22]Gupta N, Wish JB.Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD[J].Am J Kidney Dis, 2017, 69(6):815-826
